Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
G2A CRISPR/Cas9 KO Plasmid (h): sc-401866
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- G2A CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the G2A genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: G2A Antibody (G-5): sc-137112
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
G2A CRISPR/Cas9 KO Plasmid (h) | sc-401866 | 20 µg | $397.00 |
Overview
GPR132 encodes the G protein-coupled receptor G2A, an immunoregulatory sensor implicated in leukocyte trafficking and responses to inflammatory cues. G2A can be activated by extracellular acidification and bioactive lipids such as oxidized fatty acid derivatives, linking tissue stress to GPCR signaling through heterotrimeric G proteins and downstream MAPK and calcium-dependent pathways. In immune cells, G2A signaling influences chemotaxis, activation state, and cytokine-linked programs that shape inflammatory microenvironments. Dysregulated GPR132 expression or signaling has been associated with chronic inflammation and tumor–immune interactions, making it relevant for mechanistic studies in immunology and cancer biology.
G2A CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the GPR132 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the GPR132 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the GPR132 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish G2A protein expression.
This CRISPR knockout system enables efficient generation of GPR132-deficient cell models for investigation of G2A signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting GPR132 exon(s) critical for G2A function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple GPR132 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by G2A CRISPR/Cas9 KO Plasmid (h) and G2A CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the GPR132 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by G2A HDR Plasmid (h) and G2A HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by GPR132 homology arms to support homology-directed repair at defined GPR132 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.